BPC-157
Synthetic peptide derived from gastric juice showing promise for tissue repair and wound healing in animal studies.
Human Trials
2
68 participants
Risk Level
Monthly Cost
Varies significantly by source and purity; research-grade compounds cost more
Quick Facts
- Category
- Pharmaceutical
- Research Field
- Pharmacology
- Evidence Grade
- C+ – Early
- Risk Level
- Medium
- Monthly Cost
- $200 – $800
- Human Trials
- 2
Research Velocity
Mechanism of Action
BPC-157 appears to promote tissue repair through multiple pathways including angiogenesis, modulation of nitric oxide pathways, and interaction with growth hormone receptors. Research suggests it may accelerate healing by promoting blood vessel formation and reducing inflammation. The peptide also shows potential effects on the gut-brain axis and neurotransmitter systems.
Overview
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein found in human gastric juice. Initially discovered in the 1990s, this peptide has garnered significant attention in research circles for its apparent tissue-protective and healing properties. Animal studies suggest BPC-157 may accelerate wound healing, reduce inflammation, and protect various organs including the gastrointestinal tract, tendons, muscles, and even neural tissue.
The research on BPC-157 is primarily limited to animal models and in vitro studies, with only a handful of small human trials conducted to date. Studies indicate the peptide may work through multiple mechanisms including promotion of angiogenesis (blood vessel formation), modulation of growth factors, and interaction with various neurotransmitter systems. Animal research has shown promising results for treating ulcers, tendon injuries, and even some neurological conditions, though the translation of these effects to humans remains largely unproven.
Despite limited human clinical data, BPC-157 has gained popularity in biohacking and athletic communities, often used off-label for injury recovery and performance enhancement. The peptide exists in a regulatory gray area in most countries, typically available as a research chemical rather than an approved therapeutic agent. Quality and purity can vary significantly between suppliers, and long-term safety data in humans is virtually non-existent, making careful consideration essential before use.
Known Interactions
- May interact with blood clotting medications due to effects on wound healing
- Potential interactions with growth hormone therapies
- Unknown interactions with immunosuppressive medications
Legal Status by Country
Your country (United States)
Not FDA approved; available as research chemical
Available without prescription in:
Canada, Colombia, Germany, India, Mexico, Panama, Russia, United Kingdom, United States
📍 = your selected country · ✈️ = medical tourism destination · Always verify current local regulations before travel.
Key Research
- 2013
Demonstrates tissue healing properties in animal models
- 2019BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing
Reviews angiogenic mechanisms and tissue repair applications
- 2020The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity
Explores neurological and systemic effects
- 2021BPC 157: The counteraction of succinylcholine, hyperkalemia, and arrhythmias
Investigates cardiovascular protective effects
Related Interventions
17-alpha-Estradiol
Research suggests this estrogen stereoisomer may extend lifespan in male mice while avoiding feminizing effects.
Acarbose
An alpha-glucosidase inhibitor showing potential longevity benefits through metabolic modulation and caloric restriction mimetics.
Low-Dose Aspirin
Well-studied anti-platelet therapy with extensive evidence for cardiovascular protection and potential longevity benefits.
Dasatinib + Quercetin (Senolytic)
Research indicates this combination therapy may selectively eliminate senescent cells to slow aging processes.
Last verified: 2026-03-16